DRG Launches Innovative TBI Test Panel at MEDLAB Dubai

DRG Instruments GmbH ("DRG"), a renowned developer and manufacturer of immunoassays with over five decades of expertise, has announced the launch of a new division, DRG Neuroscience. This strategic expansion underscores DRG's commitment to advancing diagnostic solutions in the field of neurology. The newly formed division introduces its state-of-the-art, fully automated Chemiluminescent Immunoassay (CLIA) tests designed to evaluate suspected Traumatic Brain Injury (TBI) through the innovative GFAP and UCH-L1 combo tests.

These advanced tests are optimized for DRG's proprietary automated CLIA platform, DxDATA™, enabling rapid and precise measurement of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) levels in blood samples. The efficiency of DxDATA™ allows clinicians to obtain critical diagnostic results within just 30 minutes, provided the serum samples are collected within 12 hours of the suspected injury. This rapid turnaround time is pivotal in emergency and acute care settings, where timely decisions can significantly influence patient outcomes.

By facilitating faster and more accurate TBI assessments, DRG's tests enhance the likelihood of immediate and effective intervention. Importantly, these tests can also reduce the reliance on radiation-based diagnostic imaging, such as CT scans, which are commonly used in TBI evaluation but may expose patients to unnecessary radiation risks. This makes DRG's TBI tests a safer, more efficient alternative in many clinical scenarios.

Joerg Schloesser, Managing Director and VP of Commercial at DRG, expressed enthusiasm about the global impact of these new diagnostic tools: "We are excited to bring these innovative TBI solutions to the global market. By leveraging automated testing and rapid turnaround times, we can help healthcare professionals make quicker, more informed decisions. Our mission is to advance patient care for those affected by traumatic brain injuries worldwide."

The TBI tests have earned CE-marking, signifying compliance with European health, safety, and environmental protection standards. Additionally, they meet the stringent requirements of the Clinical and Laboratory Standards Institute (CLSI), ensuring reliability and accuracy in clinical laboratory settings. These tests are intended for use with adult patients aged 18 years and older.

Healthcare professionals interested in learning more about the availability of DRG's TBI tests can contact their local sales representatives or reach out via email at drg@drg-diagnostics.de. DRG will also be showcasing these groundbreaking tests at MEDLAB Middle East, held at the Dubai World Trade Centre from February 3 to 6, at Hall 1, Booth G50. The Product Development Team will be present to provide detailed information and address any inquiries regarding the TBI tests.